BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19638461)

  • 1. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
    Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
    PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
    Tang Z; Du R; Jiang S; Wu C; Barkauskas DS; Richey J; Molter J; Lam M; Flask C; Gerson S; Dowlati A; Liu L; Lee Z; Halmos B; Wang Y; Kern JA; Ma PC
    Br J Cancer; 2008 Sep; 99(6):911-22. PubMed ID: 19238632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
    Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC
    Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
    Serizawa M; Murakami H; Watanabe M; Takahashi T; Yamamoto N; Koh Y
    Cancer Sci; 2014 Jun; 105(6):683-9. PubMed ID: 24698130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
    Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.